Wave Life Sciences USA, Inc.

Wave Life Sciences USA, Inc. is the U.S. subsidiary of Wave Life Sciences Ltd., a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The company is dedicated to unlocking the broad potential of RNA medicines, also known as oligonucleotides, to transform human health by treating both rare and prevalent disorders. Its mission is driven by the calling to "Reimagine Possible," focusing on delivering transformative medicines to patients with serious, genetically-defined diseases.

Wave Life Sciences leverages its proprietary PRISM™ platform, which integrates multiple modalities, chemistry innovation, and deep insights into human genetics. This platform enables the design and development of RNA-targeting modalities including RNA editing (AIMers), antisense silencing, RNA interference (SpiNA), and splicing. The company's diversified pipeline includes clinical programs for obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), PNPLA3 I148M liver disease (WVE-008), Duchenne muscular dystrophy (WVE-N531), and Huntington's disease.

In recent news, Wave Life Sciences Ltd. reported its first-quarter 2026 financial results on April 28, 2026, showing increased revenue and a narrowed net loss, with a cash runway expected into the third quarter of 2028. The company is advancing its clinical programs, with multiple data readouts and regulatory milestones anticipated in 2026. Notably, in April 2026, the parent company, Wave Life Sciences Ltd., announced a plan to redomicile from Singapore to the United States, forming a new Delaware parent corporation, Wave Life Sciences, Inc., a process expected to take effect in mid-2026. Paul B. Bolno, MD, MBA, serves as the President and CEO.